Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9230342 | 1.00 | HTR2B (0.41) | HTR2BMAOAGRM2MAPK1L3MBTL1 | |
| SCHEMBL8659488 | 0.82 | HTR2B (0.37) | HTR2B | |
| SCHEMBL14168007 | 0.82 | HTR2B (0.46) | HTR2BGRM2MAPK1L3MBTL1 | |
| SCHEMBL7911772 | 0.81 | HTR2B (0.50) | HTR2BMAOAGRM2MAPK1L3MBTL1 | |
| SCHEMBL15247384 | 0.80 | PTPN1 (0.37) | GRM2MAPK1L3MBTL1 | |
| SCHEMBL4921609 | 0.80 | CYP2D6 (0.47) | HTR2BGRM2MAPK1 | |
| SCHEMBL4953038 | 0.80 | CYP2D6 (0.47) | HTR2BGRM2MAPK1 | |
| SCHEMBL14168364 | 0.80 | MAOA (0.38) | MAOAGRM2MAPK1L3MBTL1 | |
| SCHEMBL10151437 | 0.80 | MAOA (0.38) | MAOAGRM2MAPK1L3MBTL1 | |
| SCHEMBL14173675 | 0.78 | HTR2B (0.40) | HTR2BMAOAGRM2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464062-B2 | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464062-B2 | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464062-B2 | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-10-15 | — | — | US | disclosed |
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-10-15 | — | — | US | disclosed |
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-10-15 | — | — | US | disclosed |
| WO-2014085413-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-0647634-A1 | Method of preparing a heterocyclic intermediate for the production of optically active aryloxy-substituted vicinal aminoalcohols | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1995-04-12 | — | — | EP | disclosed |
| EP-0647633-A1 | Method of preparing a heterocyclic intermediate for the production of optically active aryloxysubstituted vicinal aminoalcohols | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291539-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | HTR2B, TPH2, HTR2C | HTR2B 1/4885MAOA 86/4885GRM2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.